<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676061</url>
  </required_header>
  <id_info>
    <org_study_id>020-291</org_study_id>
    <nct_id>NCT04676061</nct_id>
  </id_info>
  <brief_title>Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™</brief_title>
  <official_title>Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™; a Randomized Double-Blinded Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of norethindrone acetate (NTA) in patients with Nexplanon.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out what effects norethindrone acetate (NTA) has on the&#xD;
      duration and recurrence of frequent and/or prolonged bleeding associated with Nexplanon™.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days of bleeding and spotting</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate days of bleeding and spotting within 90-day intervals by quantifying a self-perception of amount of bleeding on a scale of 0 to 4 and associated symptoms on a scale of 0 to 10 using the Daily Dairy of Symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate quality of life by comparing the treatment and placebo groups' associated symptoms on a scale of 0 to 10 using the Daily Diary of Symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Birth Control</condition>
  <condition>Contraception</condition>
  <condition>Implant</condition>
  <condition>Breakthrough Bleeding</condition>
  <condition>Uterine Bleeding</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Norethindrone acetate (NTA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norethindrone acetate (NTA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone acetate (NTA)</intervention_name>
    <description>norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18-48&#xD;
&#xD;
          -  Between ages of 14-17 with parental/guardian permission&#xD;
&#xD;
          -  Women desiring placement of Nexplanon™&#xD;
&#xD;
          -  Willing to keep a daily symptom calendar&#xD;
&#xD;
          -  Keep appointments&#xD;
&#xD;
          -  Women not desiring to become pregnant in the next 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected Pregnancy&#xD;
&#xD;
          -  Less than 8weeks postpartum&#xD;
&#xD;
          -  Menarche less than two years ago&#xD;
&#xD;
          -  Current or past history of thrombosis or thromboembolic disorders&#xD;
&#xD;
          -  Hepatic tumors (benign or malignant)&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  Undiagnosed abnormal genital bleeding&#xD;
&#xD;
          -  Undiagnosed headaches&#xD;
&#xD;
          -  Known or suspected carcinoma of the breast or personal history of breast cancer&#xD;
&#xD;
          -  Hypersensitivity to any of the components in Nexplanon™&#xD;
&#xD;
          -  BMI greater than 40&#xD;
&#xD;
          -  Depomedroxyprogesterone acetate injection in the previous 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Stacey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Reserach Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Stacey, MD</last_name>
    <phone>254-724-4031</phone>
    <email>Joanna.Stacey@BSWHealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Stacey, MD</last_name>
      <email>Joanna.Stacey@BSWHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Richard Vargas</last_name>
      <email>Richard.Vargas@BSWHealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Hemorrhage</keyword>
  <keyword>Norethindrone Acetate</keyword>
  <keyword>Contraceptives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

